Market Research Logo

Intercept Pharmaceuticals Inc (ICPT) - Financial and Strategic SWOT Analysis Review

Intercept Pharmaceuticals Inc (ICPT) - Financial and Strategic SWOT Analysis Review

- provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Intercept Pharmaceuticals Inc (Intercept) is a biopharmaceutical company that researches, develops and commercializes treatments for non-viral, progressive liver diseases. It develops products using its proprietary bile acid chemistry. The company’s lead product candidate, obeticholic acid (OCA), is a bile acid analog and first-in-class agonist of the farnesoid X receptor. The company owns worldwide rights to OCA except for China, Japan and Korea, where the rights were exclusively licensed to Sumitomo Dainippon Pharma Co., Ltd., (Sumitomo Dainippon) along with an option to exclusively license OCA in certain other Asian countries. The product is also under development for the treatment of various other liver diseases. Intercept’s other developmental products in pipeline include INT-767 for the treatment of fibrosis; and INT-777 for type 2 diabetes. Intercept is headquartered in New York, the US.

Intercept Pharmaceuticals Inc Key Recent Developments

Feb 14,2018: Intercept Pharmaceuticals Reports Net Sales Of $129.2 Million For The Year Ended December 31, 2017
Nov 27,2017: Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development
Jul 31,2017: Intercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
Jun 22,2017: Intercept's primary biliary cholangitis treatment wins 2017 Premio Galeno Italia Chemical Synthesis Drug Award
May 19,2017: Intercept receives 2017 Industry Innovation Award from NORD for primary biliary cholangitis therapy

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company


Section 1 - About the Company
Intercept Pharmaceuticals Inc - Key Facts
Intercept Pharmaceuticals Inc - Key Employees
Intercept Pharmaceuticals Inc - Key Employee Biographies
Intercept Pharmaceuticals Inc - Major Products and Services
Intercept Pharmaceuticals Inc - History
Intercept Pharmaceuticals Inc - Company Statement
Intercept Pharmaceuticals Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Section 2 – Company Analysis
Company Overview
Intercept Pharmaceuticals Inc - Business Description
R&D Overview
Intercept Pharmaceuticals Inc - Corporate Strategy
Intercept Pharmaceuticals Inc - SWOT Analysis
SWOT Analysis - Overview
Intercept Pharmaceuticals Inc - Strengths
Intercept Pharmaceuticals Inc - Weaknesses
Intercept Pharmaceuticals Inc - Opportunities
Intercept Pharmaceuticals Inc - Threats
Intercept Pharmaceuticals Inc - Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Intercept Pharmaceuticals Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Nov 27, 2017: Intercept Pharmaceuticals Appoints Christian Weyer as Executive Vice President of Research & Development
Jul 31, 2017: Intercept Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Business Update
Jun 22, 2017: Intercept's primary biliary cholangitis treatment wins 2017 Premio Galeno Italia Chemical Synthesis Drug Award
May 19, 2017: Intercept receives 2017 Industry Innovation Award from NORD for primary biliary cholangitis therapy
May 04, 2017: Intercept Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Business Update
Feb 23, 2017: Intercept Pharmaceuticals Reports Full Year 2016 Financial Results and Provides Business Update
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer
List of Tables
Intercept Pharmaceuticals Inc, Key Facts
Intercept Pharmaceuticals Inc, Key Employees
Intercept Pharmaceuticals Inc, Key Employee Biographies
Intercept Pharmaceuticals Inc, Major Products and Services
Intercept Pharmaceuticals Inc, History
Intercept Pharmaceuticals Inc, Other Locations
Intercept Pharmaceuticals Inc, Subsidiaries
Intercept Pharmaceuticals Inc, Key Competitors
Intercept Pharmaceuticals Inc, Ratios based on current share price
Intercept Pharmaceuticals Inc, Annual Ratios
Intercept Pharmaceuticals Inc, Annual Ratios (Cont...1)
Intercept Pharmaceuticals Inc, Interim Ratios
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Intercept Pharmaceuticals Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios
List of Figures
Intercept Pharmaceuticals Inc, Performance Chart (2013 - 2017)
Intercept Pharmaceuticals Inc, Ratio Charts
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Intercept Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report